Generex Biotechnology extends scope of U.S. patent protection for vaccine technology
Generex Biotechnology Corporation announced that that its wholly owned subsidiary, Antigen Express, Inc., has received a Notice of Allowance in connection with US Patent Application No. 10/197,000 entitled Hybrid peptides Modulate the Immune Response. The specific award covers fundamental aspects of the design and use of Ii-Key antigenic epitope hybrids in treating disease.
According to the company, potentiation of the therapeutic and prophylactic potency of vaccines using Ii-Key hybrids is a core component of Antigen Express technology. Ii-Key is a small fragment of the MHC class II associated invariant chain (Ii protein) that works by increasing the ability of specific antigens to stimulate T helper cells. Antigen Express has recently initiated a Phase II clinical trial designed to test the efficacy of one of its immunotherapeutic Ii-Key hybrid vaccines (AE37) in breast cancer. It has also initiated clinical trials on a synthetic avian influenza vaccine designed using the same principal.
Other news from the department research and development
